Anti-Human CD279 (PD-1) (Nivolumab)
Anti-Human CD279 (PD-1) (Nivolumab)
Product No.: LT1200
- -
- -
Product No.LT1200 Clone 5C4.B8 Target PD-1 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1 Isotype Human IgG1κ Applications B , FA , FC , IHC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human/Cynomolgus Monkey Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human PD-1 Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893893 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC FA FC B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only. Background Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects. Antigen Distribution PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. Ligand/Receptor PD-L1 and PD-L2 PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immuno-Oncology . Immunology References & Citations1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293–97. 2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):846-56. 3. Li, Y. et al. (2016) MAbs. 8(5):951-60. 4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.